Amryt Pharma Share Chat (AMYT)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Amryt Pharma	LSE:AMYT	London	Ordinary Share	GB00BDD1LS57	ORD 1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.00p	+0.00%	21.75p	21.00p	22.50p	21.75p	21.75p	21.75p	114,100	08:00:00

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	1.2	-6.7	-4.1	-	45.31

Amryt Pharma Share Discussion Threads

Showing 1776 to 1798 of 1800 messages

Chat Pages: 72 71 70 69 68 67 66 65 64 63 62 61 Older

Date	Subject	Author	Discuss
25/9/2017 14:40	Happy Monday folks! :-) She's holding firm enough at the current price Paps, I still see that as the share price being about 10-12% higher than what is was before the placing so more than happy with that for now.	greendragon777	Read Full Thread Reply
25/9/2017 12:51	Buys are going through below mid price @ around 21.60p. Sells around 21.10p. A further drop in the "official" share price is looking possible (in fact looking at the current buying and selling price it's already happened!). ATB. The Paper Boy! LOL	papillon	Read Full Thread Reply
24/9/2017 23:28	Since the start of the year the share price has dropped back to the 200 day SMA twice (dropping just below both times); at the start of February and at the end of August (actually the 200 day SMA prior to the middle of January shouldn't show on the advfn chart I've posted because before then AMYT hadn't traded for 200 days so the 200 day SMA line prior to the middle of January shown on the chart is meaningless). It's possible the share price is going to do the same again in the short term (it hasn't got that far to go due to the fall in the share price on the placing news). The 200 day SMA is in a rising trend and the AMYT chart looks bullish to me, with the proviso that a share chart is only an historical record. The longer term trend (in the case of AMYT going back to December) is generally stronger than the shorter term trend (in the case of AMYT going back to the start of April) so I'm quietly confident that the AMYT will soon start rising again and this could be an excellent time, IMO, to top up. PS: As an ex paper boy (retiring from my paper round 7 years ago when reaching the ago of 65) and of limited financial means (only hold 18,500 shares) everything I post should be taken with a large pinch of salt!	papillon	Read Full Thread Reply
24/9/2017 10:49	AMYT chart. Make of it what you will: free stock charts from uk.advfn.com	papillon	Read Full Thread Reply
24/9/2017 10:33	Point taken, blomers. I'll stop reading the lse AMYT bb.	papillon	Read Full Thread Reply
24/9/2017 01:11	Umm. I'm a bit confused. This is the advfn bb. I don't know who congemi and tuchehagen are. Although they do sound like idiots, they are lse idiots. I'd much rather stick to posts relevant to the advfn thread rather than replaying a feud from another bb that's entirely irrelevant on this bb. I'm sick of having to put up with trolls on other shares (KIBO is unreadable now). I don't really want to read 2nd hand trolling from another site.	blomers	Read Full Thread Reply
23/9/2017 22:28	Tuchenhagen. You quickly came to Congemi's defence when I criticised him. It may just be coincidence, but both you and Congemi post on the same two shares: AMYT & PVR. You only post on those and almost all of Congemi's posts are on them. You also have a "love in" on the go; you praise his posts and he praises yours. Are you the same person by any chance? You have two things in common apart from your shared interest in AMYT & PVR: you're both liars and morons.	papillon	Read Full Thread Reply
23/9/2017 21:36	Well I agree, waterloo. AMYT is a STONKING BUY at the current price, IMO. Unfortunately the general market doesn't agree going by the AMYT Mkt Cap. That could change of course. Fingers crossed!	papillon	Read Full Thread Reply
23/9/2017 14:18	Amryt Pharma – placing disappointment, my anger as a shareholder, CEO chat - BUY htTps://www.shareprophets.com/views/31730/amryt-pharma-placing-disappointment-my-anger-as-a-shareholder-ceo-chat-buy	waterloo01	Read Full Thread Reply
22/9/2017 17:48	Congemi Posts: 289 Off Topic Opinion: No Opinion Price: 22.00 Episalvan Today 16:45 I'm wondering if the market size is so big why hasn't another pharma company invested in the secondary.Something does not add up here. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> The Brain of Britain is at it again! I know what doesn't add up, Congemi; your thought processes! Until last week there were 2 players going for this 1.3bn Euro market and one has now dropped out and it was the player in the lead and with the most dosh, leaving just AMYT. Until last week 2 players seemed about right for the size of the market, chances of success and the financial outlay necessary to develop and pass the regulatory hurdles. It's now a bit LATE for another entrant because AMYT has such a lead and any new entrant would need to pass phase 1, 2 & 3. It would take years, by which time Episalvan could (big IF) have the market already sown up. PS. There is no doubt in my mind that the placing process (approaching institutional and other investors) was started some time ago; possibly before the interim results were issued and was why the share price drifted down towards 20p. After all why would anyone approached to take part in a placing at 20p buy in the market at a higher price? The temptation would be to sell, or short, if you were a holder, or non holder, and were approached to take part (not saying anyone did! LOL). Whenever the placing process was ongoing I'd bet money it was before we received the news that Amicus were aborting the Zorblisa phase 3 trial. Did that news come out of the blue to AMYT as well as us ignorant PI's? I reckon it did! I wonder if AMYT had known that Zorblisa was dead in the water they would have arranged this placing at this particular time? I've got my doubts about that; I reckon they might have waited to see if the share price was going to rise on the Zorblisa news and hence got the placing away at a higher price in the future. PPS. It looked likely, prior to the Zorblisa news last week, that Zorblisa, being in front of Episalvan, would get a far bigger slice of that 1.3bn Euro cake than Episalvan. It now looks like Episalvan will have that 1.3bn Euro cake all to itself if it proves to be an effective treatment for EB (big IF). To me that should signal a big re-rating of the AMYT share price However, as always, what I think is immaterial; it's what other investors think that's important. I do think, however, that the penny will soon drop and we will soon see a much higher share price in the short term (say, within next few months).	papillon	Read Full Thread Reply
22/9/2017 14:41	I think someone needs to do him a favour and liquidate his shares for him....he'll sleep better at night as a result! 😁 It would be hilarious if he dumped all his shares about a week before a takeover bid came in! 😂😂😂	greendragon777	Read Full Thread Reply
22/9/2017 13:57	Unfortunately, greendragon, Congemi is as thick as two short planks. He posts this today: "I want to know why if Episalvan has a potential €1.3 billion market and its main competitor has blown up why is the company trading at a 45 million market cap?Someone is lying! and thats not including Lujuxta revenues. I think that is a valid question and makes me question what the BOD are really doing!" What Congemi is completely ignoring is the fact that Episalvan is NOT YET PROVEN as a remedy for EB. It's like an O&G being currently valued at, say £50m, even though it's about to drill an exploration well that if successful could make the company worth £500m. The reason why that O&G is only valued at £50m is because they haven't yet found the oil and they may not find it. The same applies to AMYT with Episalvan; it's not yet proven as an effective remedy for EB and may not be. Also the company IS NOT valued at £45m. That's the current Mkt Cap, but Congemi hasn't included the extra shares being issued due to the 15m Euro placing AND THE 20m Euro EIB loan!! At the current share price the REAL value of AMYT is closer to £75m!! So we have a company currently valued at £75m (that EIB loan has to be repaid) and with current revenue from Lojuxta of just circa 11.5m Euro's and a cream, Episalvan, that MAY, OR MAY NOT, prove efficacious for treating EB with a potential annual 1.3bn Euro market. I think the only one lying is Congemi; either that or he's got very little between his ears! Probably the latter. Someone needs to question Congemi's thought processes!	papillon	Read Full Thread Reply
22/9/2017 12:34	He did indeed, greendragon. He predicted that the share price was going back to 14p just before the interim results were issued on the 4th. I don't mind his posts; one needs to read an opposing opinion, but why he continues to hold AMYT if he REALLY believes the share price is going below 20p and has such a negative opinion of the company and it's prospects beggars belief. He should sell. I know I would if I held his opinions.	papillon	Read Full Thread Reply
22/9/2017 12:13	Didn't that guy Congemi also 'predict' that the share price was gonna hit 14p a while back? I've seen a few of his posts over there and it's beggars believe why he doesn't bail out his position on AMYT never to return. Why get involved in something you practically despise, I just don't get it! Sorry to hear about you back Paps, there's nothing worse. Hopefully it'll get better in time or with some treatment.	greendragon777	Read Full Thread Reply
22/9/2017 11:45	There's an IDIOT who posts on the lse bb called Congemi. He thinks he can predict the future! Let's see if he is proves to be correct this time, or proves to be the whinging Wally he appears to be! LOL. "well under .20 by" Oct 9th. LOL. He's ignoring the fact that the placing at 20p was oversubscribed! LOL. Congemi Posts: 284 Off Topic Opinion: No Opinion Price: 22.00 Shareholder meeting Oct 9th Today 08:53 Im betting we will be well under .20 by then.	papillon	Read Full Thread Reply
21/9/2017 23:40	I'm suffering from a lack of sleep at the moment (due to a bout of painful sciatica), bwd, so I think I will play that Joe Wiley interview (many thanks for providing the link); it might get me off to sleep! Probably better than counting sheep and less harmful to my liver than resorting to alcohol! LOL.	papillon	Read Full Thread Reply
21/9/2017 23:20	I haven't listened to it (yet) but an interview with Joe Wiley about the placing is here: hTTps://audioboom.com/posts/6322339-joe-wiley-ceo-of-amryt-pharma-amyt	bigwavedave	Read Full Thread Reply
21/9/2017 21:40	The share price was lower than todays closing price less than 3 weeks ago, pottermagic2310. Unfortunately almost all AIM natural resource explorers and biotechs return over and over again to the market to raise cash via placings, pottermagic. It's the name of the game, unfortunately, when you lack a revenue stream (or big enough revenue stream in AMYT's case) to fund their ongoing exploration (for a natural resource explorer), or fund phase 1, 2, or 3 trials (for a biotech). Do you live in the real world, pottermagic? AMYT have only had this one placing since flotation. I can name any number of AIM companies with a lot more placings to their name!! Placings and hence dilution are an occupational hazard if you invest on AIM. You must have been extremely lucky if you have never been invested in an AIM company where a placing and hence dilution occurs with a resultant drop in the share price on the news. Let's be realistic; if Lojuxta sales don't live up to expectations and AP101 is not efficacious in treating EB skin conditions then today wont be the last AMYT placing and they wont be anywhere near as high as 20p! Look at VAL for an example of a biotech disaster zone. Even if Lojuxta does live up to expectations and AP101 proves to be successful then AMYT could still raise money via a placing, but it would be at a much higher price than 20p!! PS. Why do you have to average down, pottermagic? The share price has only dropped by less than 15% today. Will it drift lower? No idea! I topped up when the share price was circa 22p and also 3 weeks ago when it was circa 20p so I have no need to top up. Today's placing is a set back, but in the scheme of things not a disaster. It hasn't changed my opinion of AMYT's future prospects. AMYT is a good gamble IMO, but a gamble none the less. Hope for the best, but fear the worst. That way you wont gamble more than you can afford to lose!	papillon	Read Full Thread Reply
21/9/2017 21:01	Still... 25% dilution is still a kick in the nuts. Got to either suck it up or average down with whatever low now occurs - sub 20p ??	pottermagic2310	Read Full Thread Reply
21/9/2017 19:12	Waterloo,I too like the sound of the forward-looking view - investing in enablers to progress AP101 sales on a successful Phase 3 outcome. However, I do wish there was an update on the enrolment of the EB sufferers into that trial.Cheers, tightfist	tightfist	Read Full Thread Reply
21/9/2017 18:15	"CEO Joe Wiley will feel the impact of share dilution more than I will" It wont dilute his salary though will it, diamondstar? LOL. Obviously Cathal Friel will feel the adverse effects of the circa 15% decline in the sp, but the dilution in itself is not material; the only material aspect of a placing is what impact it has on the share price short term. I don't worry about dilution either apart from any adverse effect it has on the share price I would have liked to have seen the placing done at more than 20p, but I've no doubt that the share price will soon recover and go higher now that funding is sorted. No use crying over spilt milk. Future funding was a Sword of Damocles hanging over the share price That's now gone. Buying AMYT shares is a GAMBLE, IMO, but a GOOD one. Not for widows and orphans though and don't bet money you can't afford to lose.	papillon	Read Full Thread Reply
21/9/2017 18:10	I share your miffed-ness with today's placing - just as we had some momentum and visible paper profit, this has (temporarily) wiped it out. I do however remain positive - and even more positive when I read the throw-away line in the RNS: "As we develop the business further, we will consider additional in-licensing opportunities, as well as acquisitions or investments in other promising assets." Much easier to swoop on an opportunity when you have a gigantic pile of cash ;)	speccy1	Read Full Thread Reply
21/9/2017 18:09	If the company hit their Lojuxta sales targets, which they look likely to beat, it still leaves AP101 virtually un-valued and in the light of the Amicus deal, and recent failure, plainly undervalues the company as it leads toward the pivotal interim readout.	waterloo01	Read Full Thread Reply

Chat Pages: 72 71 70 69 68 67 66 65 64 63 62 61 Older